A citation-based method for searching scientific literature

Paresh Dandona, Chantal Mathieu, Moshe Phillip, Lars Hansen, Steven C Griffen, Diethelm Tschöpe, Fredrik Thorén, John Xu, Anna Maria Langkilde. Lancet Diabetes Endocrinol 2017
Times Cited: 156







List of co-cited articles
640 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Selective sodium-dependent glucose transporter 1 inhibitors block glucose absorption and impair glucose-dependent insulinotropic peptide release.
Robert L Dobbins, Frank L Greenway, Lihong Chen, Yaping Liu, Sharon L Breed, Susan M Andrews, Jeffrey A Wald, Ann Walker, Chari D Smith. Am J Physiol Gastrointest Liver Physiol 2015
66
6

Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function.
Brendon L Neuen, Toshiaki Ohkuma, Bruce Neal, David R Matthews, Dick de Zeeuw, Kenneth W Mahaffey, Greg Fulcher, Mehul Desai, Qiang Li, Hsiaowei Deng,[...]. Circulation 2018
126
4

Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials.
Roy W Beck, Richard M Bergenstal, Tonya D Riddlesworth, Craig Kollman, Zhaomian Li, Adam S Brown, Kelly L Close. Diabetes Care 2019
209
4

Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.
Wei Meng, Bruce A Ellsworth, Alexandra A Nirschl, Peggy J McCann, Manorama Patel, Ravindar N Girotra, Gang Wu, Philip M Sher, Eamonn P Morrison, Scott A Biller,[...]. J Med Chem 2008
366
4

SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects.
Ele Ferrannini, Anna Solini. Nat Rev Endocrinol 2012
257
4

Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008-2010.
Shona J Livingstone, Daniel Levin, Helen C Looker, Robert S Lindsay, Sarah H Wild, Nicola Joss, Graham Leese, Peter Leslie, Rory J McCrimmon, Wendy Metcalfe,[...]. JAMA 2015
265
4

Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized, open label study.
K V S Hari Kumar, Altamash Shaikh, Pitambar Prusty. Diabetes Res Clin Pract 2013
61
6

Twelve-Week Treatment With Liraglutide as Add-on to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blind Parallel Study.
Christian S Frandsen, Thomas F Dejgaard, Jens J Holst, Henrik U Andersen, Birger Thorsteinsson, Sten Madsbad. Diabetes Care 2015
52
7




Insulin resistance in type 1 diabetes: what is 'double diabetes' and what are the risks?
S J Cleland, B M Fisher, H M Colhoun, N Sattar, J R Petrie. Diabetologia 2013
104
4

Influence of Dapagliflozin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes Mellitus.
Feng-Fei Li, Gu Gao, Qian Li, Hong-Hong Zhu, Xiao-Fei Su, Jin-Dan Wu, Lei Ye, Jian-Hua Ma. J Diabetes Res 2016
15
26

SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis.
Brendon L Neuen, Tamara Young, Hiddo J L Heerspink, Bruce Neal, Vlado Perkovic, Laurent Billot, Kenneth W Mahaffey, David M Charytan, David C Wheeler, Clare Arnott,[...]. Lancet Diabetes Endocrinol 2019
211
4

The efficacy and safety of DPP4 inhibitors in patients with type 1 diabetes: A systematic review and meta-analysis.
Heming Guo, Chen Fang, Yun Huang, Yufang Pei, Linqi Chen, Ji Hu. Diabetes Res Clin Pract 2016
34
11


Sotagliflozin Added to Optimized Insulin Therapy Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c at 52 Weeks in Adults with Type 1 Diabetes.
Thomas Danne, Jeremy Pettus, Andrea Giaccari, Bertrand Cariou, Helena Rodbard, Stuart A Weinzimer, Mireille Bonnemaire, Sangeeta Sawhney, John Stewart, Stella Wang,[...]. Diabetes Technol Ther 2019
9
44

What does sodium-glucose co-transporter 1 inhibition add: Prospects for dual inhibition.
Jessica A Dominguez Rieg, Timo Rieg. Diabetes Obes Metab 2019
23
17

Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.
Ofri Mosenzon, Stephen D Wiviott, Avivit Cahn, Aliza Rozenberg, Ilan Yanuv, Erica L Goodrich, Sabina A Murphy, Hiddo J L Heerspink, Thomas A Zelniker, Jamie P Dwyer,[...]. Lancet Diabetes Endocrinol 2019
238
4

Systematic literature review and network meta-analysis of sodium-glucose co-transporter inhibitors vs metformin as add-on to insulin in type 1 diabetes.
Bryony E Langford, Marc Evans, Tao Haskins-Coulter, Molly O'Connor, Harriet E O Cant, Lucy A Eddowes, Christopher Edmonds, Amarjeet Tank. Diabetes Obes Metab 2020
6
66

SGLT Inhibitors for Type 1 Diabetes: An Obvious Choice or Too Good to Be True?
Matthew C Riddle, William T Cefalu. Diabetes Care 2018
10
40

Prevalence and comorbidities of double diabetes.
S R Merger, W Kerner, M Stadler, A Zeyfang, P Jehle, M Müller-Korbsch, R W Holl. Diabetes Res Clin Pract 2016
37
10

Sotagliflozin Decreases Postprandial Glucose and Insulin Concentrations by Delaying Intestinal Glucose Absorption.
David R Powell, Brian Zambrowicz, Linda Morrow, Carine Beysen, Marcus Hompesch, Scott Turner, Marc Hellerstein, Phillip Banks, Paul Strumph, Pablo Lapuerta. J Clin Endocrinol Metab 2020
13
30


Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS data.
Jenny E Blau, Sri Harsha Tella, Simeon I Taylor, Kristina I Rother. Diabetes Metab Res Rev 2017
76
3

SGLT2 Protein Expression Is Increased in Human Diabetic Nephropathy: SGLT2 PROTEIN INHIBITION DECREASES RENAL LIPID ACCUMULATION, INFLAMMATION, AND THE DEVELOPMENT OF NEPHROPATHY IN DIABETIC MICE.
Xiaoxin X Wang, Jonathan Levi, Yuhuan Luo, Komuraiah Myakala, Michal Herman-Edelstein, Liru Qiu, Dong Wang, Yingqiong Peng, Almut Grenz, Scott Lucia,[...]. J Biol Chem 2017
127
3

Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial.
Hans-Ulrich Häring, Ludwig Merker, Elke Seewaldt-Becker, Marc Weimer, Thomas Meinicke, Uli C Broedl, Hans J Woerle. Diabetes Care 2014
252
3


Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials.
Serge Jabbour, Jochen Seufert, Andre Scheen, Clifford J Bailey, Cathrina Karup, Anna M Langkilde. Diabetes Obes Metab 2018
78
3


Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes.
Bruce Neal, Vlado Perkovic, Dick de Zeeuw, Kenneth W Mahaffey, Greg Fulcher, Kirk Ways, Mehul Desai, Wayne Shaw, George Capuano, Maria Alba,[...]. Diabetes Care 2015
156
3


SGLT2 inhibition--a novel strategy for diabetes treatment.
Edward C Chao, Robert R Henry. Nat Rev Drug Discov 2010
403
3

The mechanisms of action of metformin.
Graham Rena, D Grahame Hardie, Ewan R Pearson. Diabetologia 2017
632
3

Liraglutide as additional treatment to insulin in obese patients with type 1 diabetes mellitus.
Nitesh D Kuhadiya, Ritu Malik, Natalie J Bellini, Jane Lyons Patterson, Andrea Traina, Antoine Makdissi, Paresh Dandona. Endocr Pract 2013
55
5

Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical Trial.
Wendy Lane, Timothy S Bailey, Gregg Gerety, Janusz Gumprecht, Athena Philis-Tsimikas, Charlotte Thim Hansen, Thor S S Nielsen, Mark Warren. JAMA 2017
114
3

Definitions of terrorism.
Robert Lipton, Jess H Ghannam, Joel Beinin. JAMA 2003
28
10



Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research.
Philip A Levin, Hiep Nguyen, Eric T Wittbrodt, Seoyoung C Kim. Diabetes Metab Syndr Obes 2017
50
6

Effect of patients' risks and preferences on health gains with plasma glucose level lowering in type 2 diabetes mellitus.
Sandeep Vijan, Jeremy B Sussman, John S Yudkin, Rodney A Hayward. JAMA Intern Med 2014
115
3

Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis.
Sonal Singh, Eugene E Wright, Anita Y M Kwan, Juliette C Thompson, Iqra A Syed, Ellen E Korol, Nathalie A Waser, Maria B Yu, Rattan Juneja. Diabetes Obes Metab 2017
43
6

Insulin Access and Affordability Working Group: Conclusions and Recommendations.
William T Cefalu, Daniel E Dawes, Gina Gavlak, Dana Goldman, William H Herman, Karen Van Nuys, Alvin C Powers, Simeon I Taylor, Alan L Yatvin. Diabetes Care 2018
88
3


Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes.
Michaela Diamant, Michael A Nauck, Rimma Shaginian, James K Malone, Simon Cleall, Matthew Reaney, Danielle de Vries, Byron J Hoogwerf, Leigh MacConell, Bruce H R Wolffenbuttel. Diabetes Care 2014
148
3

Safety, effectiveness, and cost effectiveness of long acting versus intermediate acting insulin for patients with type 1 diabetes: systematic review and network meta-analysis.
Andrea C Tricco, Huda M Ashoor, Jesmin Antony, Joseph Beyene, Areti Angeliki Veroniki, Wanrudee Isaranuwatchai, Alana Harrington, Charlotte Wilson, Sophia Tsouros, Charlene Soobiah,[...]. BMJ 2014
54
5

Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long).
Bernard Zinman, Athena Philis-Tsimikas, Bertrand Cariou, Yehuda Handelsman, Helena W Rodbard, Thue Johansen, Lars Endahl, Chantal Mathieu. Diabetes Care 2012
224
3

New Insulin Delivery Recommendations.
Anders H Frid, Gillian Kreugel, Giorgio Grassi, Serge Halimi, Debbie Hicks, Laurence J Hirsch, Mike J Smith, Regine Wellhoener, Bruce W Bode, Irl B Hirsch,[...]. Mayo Clin Proc 2016
95
3

Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study.
H Yki-Järvinen, R Kauppinen-Mäkelin, M Tiikkainen, M Vähätalo, H Virtamo, K Nikkilä, T Tulokas, S Hulme, K Hardy, S McNulty,[...]. Diabetologia 2006
300
3

Insulin and Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Maria Ida Maiorino, Paolo Chiodini, Giuseppe Bellastella, Annalisa Capuano, Katherine Esposito, Dario Giugliano. Diabetes Care 2017
57
5


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.